Central Nervous System News and Research

RSS

Exercise may help fibromyalgia: Study

A new study shows that fibromyalgia patients who stopped taking medication but exercised regularly for six weeks reported improved memory function and less pain. While the finding is encouraging, it does not suggest a potential change in clinical care for fibromyalgia patients, the study authors stressed.

15 Nov 2011

Scil Proteins completes manufacturing agreement with Lundbeck

Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today the successful completion of a manufacturing agreement for Lundbeck, an international pharmaceutical company specializing in central nervous system disorders.

15 Nov 2011

Global demand to join pioneering adult stem cell study to treat ALS

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, today announced that patients from across the globe are demanding to be included in the pioneering clinical study started earlier this year at Jerusalem's Hadassah University Medical Center.

14 Nov 2011

Study uses fMRI to assess changes in brain after exercise intervention

Areas of the brain responsible for pain processing and cognitive performance changed in fibromyalgia patients who exercised following a medication holiday, say researchers from Georgetown University Medical Center. They say the changes indicate brain functioning is more streamlined after an exercise intervention because less of the brain-s resources is devoted to processing bothersome fibromyalgia perceptions such as pain.

14 Nov 2011

China Pharma third quarter revenue increases 12% to $21.0 million

China Pharma Holdings, Inc., a specialty pharmaceuticals company in China, today announced financial results for the quarter ended September 30, 2011.

11 Nov 2011

Worm model to evaluate drugs for Parkinson's disease

Researchers at The University of Texas at Austin have devised a simple test, using dopamine-deficient worms, for identifying drugs that may help people with Parkinson's disease.

11 Nov 2011

Rensselaer engineer receives $1.4M NIH grant to study new method to heal traumatic nerve damage

Injuries to the nervous system affect large numbers of people globally. Such injuries can result in loss of feeling or movement. With a new $1.4 million grant from the National Institutes of Health, Deanna Thompson, associate professor of biomedical engineering at Rensselaer Polytechnic Institute, will investigate a promising new method to heal traumatic nerve damage, using electrical stimulation to prime and pump neuronal growth.

10 Nov 2011

Experimental drug selectively destroys blood supply of fat tissue and decreases body fat

Obese rhesus monkeys lost on average 11 percent of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in Science Translational Medicine.

10 Nov 2011

New cellular targets for devastating neurological disorder

In a paper published in the November 9 issue of The Journal of Neuroscience, researchers at the University of California, San Diego School of Medicine and University of Washington describe in deeper detail the pathology of a devastating neurological disorder, but also reveal new cellular targets for possibly slowing its development.

10 Nov 2011

Clinilabs to utilize NewCardio's QTinno in Phase I trial of new CNS drug

NewCardio, Inc., a cardiovascular diagnostic solutions developer, announced today that its strategic partner, Clinilabs, will utilize QTinno, NewCardio's automated cardiac safety solution, to conduct a Phase I trial of an investigational new drug under development for a central nervous system (CNS) indication.

10 Nov 2011

ACADIA third quarter revenues decrease to $584,000

9 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

Study reveals need for defining optimal amount of iron in infant formula

A 10-year follow-up study examining iron-fortified vs. low-iron infant formula suggests that infants with high hemoglobin levels who received iron fortified infant formula have poorer long-term developmental outcomes.

9 Nov 2011

Omeros third quarter net loss decreases to $6.5 million

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2011.

9 Nov 2011

Brain plays a key role in regulating glucose metabolism in humans

Researchers at Albert Einstein College of Medicine of Yeshiva University have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.

7 Nov 2011

ACADIA and Meiji Seika collaborate to develop AM-831 for schizophrenia treatment

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, an innovative small molecule for the treatment of schizophrenia.

7 Nov 2011

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Human Genome Sciences, Inc. announced today that several abstracts related to BENLYSTA (belimumab) and systemic lupus erythematosus will be presented at the annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals, being held in Chicago, IL from November 4 to November 9, 2011.

5 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Vanda third quarter total revenues increase to $8.0 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2011.

4 Nov 2011

Study reveals new role for the 'hormone of love'

Much of the body's chemistry is controlled by the brain - from blood pressure to appetite to food metabolism. In a study published recently in Developmental Cell, a team of scientists led by Dr. Gil Levkowitz of the Weizmann Institute has revealed the exact structure of one crucial brain area in which biochemical commands are passed from the brain cells to the bloodstream and from there to the body. In the process, they discovered a surprising new role for the 'hormone of love,' showing that it helps to direct the development of this brain structure.

3 Nov 2011